1. Home
  2. Medical News
  3. Geriatrics
advertisement

PSA Screening After 70: Modeled Harms Rise With Comorbidity

Simplified prostate gland with subtle tissue irregularity illustrating prostate cancer screening and potential overdiagnosis
11/20/2026

Key Takeaways

  • Among previously screened men entering their 70s without a prostate cancer diagnosis, the modeled ratio of overdiagnoses to prostate cancer deaths prevented rose with age.
  • Severe comorbidity carried at least double the age-matched ratio seen without comorbidity.
  • Under MRI-based evaluation, selective continuation based on PSA yielded a similar ratio to continued screening of all eligible older men.
For a previously screened man in his 70s, continuing prostate-specific antigen (PSA) screening raises a question about potential reductions in prostate cancer mortality versus the risk of overdiagnosis. Investigators modeled how age and comorbidity might affect the outcomes of continued screening.

Investigators used two microsimulation models in an analysis of continued biennial prostate cancer screening. The modeled men had undergone PSA screening every two years from ages 50 through 70 and had no prostate cancer diagnosis at age 72. The models projected overdiagnoses per prostate cancer death prevented over the remaining lifetime, using previously estimated comorbidity-adjusted life tables to account for competing mortality.

With a PSA threshold of 6.5 nanograms per milliliter (ng/mL), further evaluation involved magnetic resonance imaging (MRI) and MRI-targeted biopsy. At age 72, the models estimated 2.7–3.1 overdiagnoses per prostate cancer death prevented among men without comorbidities, compared with 9.6–10.2 among men with severe comorbidities.

At age 76, the estimated ratios were 4.5–5.1 overdiagnoses per prostate cancer death prevented without comorbidities and 11.3–12.6 with severe comorbidities. The ratios were described as similar whether screening continued for all eligible older men or only for those whose PSA was ≥3.0 ng/mL.

These remaining-lifetime microsimulation projections are not observed trial outcomes and cannot predict whether an individual man would benefit from screening. Competing mortality affects the opportunity for a prostate cancer mortality benefit to emerge, but the modeled ratios do not establish how diagnosed cancers were managed or characterize unreported safety outcomes.

The authors concluded that continued screening should be limited to select older men with sufficient life expectancy, though their projections do not establish a universal stopping age.

Clinician Questions

What counts as overdiagnosis when PSA screening continues in older men?

In continued prostate-specific antigen screening of older men, overdiagnosis means a prostate cancer diagnosis that would not have occurred during that man's lifetime without screening. It concerns whether the cancer is diagnosed, not whether a diagnosed cancer receives treatment; overdiagnosis is not synonymous with overtreatment.

Recommended Reading

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free